The stock of Acadia Pharmaceuticals Inc (NASDAQ:ACAD) last traded at $18.35, up 9.95% from the previous session.
ACAD stock price is now 11.34% away from the 50-day moving average and 11.82% away from the 200-day moving average. The market capitalization of the company currently stands at $3.36B.
Top 5 Artificial Intelligence Stocks to Buy for 2024
By now, you're well aware of the artificial intelligence boom. You know Big Tech has been investing billions of dollars into it.
According to Next Move Strategy Consulting, the AI market – currently valued at about $100 billion – cold grow twenty-fold by 2030 to more than $2 trillion. That means you may want to strongly consider these top AI stocks. Get our free report, "Top 5 AI Stocks to Buy in 2024."
Click here to automatically get the our FREE Report & Special Offer "5 Best AI Stocks to Invest In"
Sponsored
On August 07, 2024, Morgan Stanley Downgraded its previous ‘Overweight’ rating to ‘Equal-Weight’ on the stock reducing its target price from $28 to quote $20, while ‘BMO Capital Markets’ rates the stock as ‘Outperform’
In other news, Teehan Brendan, EVP, COO, HEAD OF COMMERCIAL sold 10,329 shares of the company’s stock on Nov 19 ’24. The stock was sold for $173,630 at an average price of $16.81. Upon completion of the transaction, the EVP, COO, HEAD OF COMMERCIAL now directly owns 62,105 shares in the company, valued at $1.14 million. An SEC document containing details of the transaction can be found on the SEC’s website. On Nov 19 ’24, PRINCIPAL ACCOUNTING OFFICER Kihara James sold 4,073 shares of the business’s stock. A total of $68,467 was realized by selling the stock at an average price of $16.81. This leaves the insider owning 19,863 shares of the company worth $0.36 million. A total of 1.26% of the company’s stock is owned by insiders.
During the past 12 months, Acadia Pharmaceuticals Inc has had a low of $14.15 and a high of $31.82. As of last week, the company has a debt-to-equity ratio of 0.09, a current ratio of 2.29, and a quick ratio of 2.11. The fifty day moving average price for ACAD is $16.4814 and a two-hundred day moving average price translates $16.41065 for the stock.
The latest earnings results from Acadia Pharmaceuticals Inc (NASDAQ: ACAD) was released for 2024-09-30. The net profit margin was 13.83% and return on equity was 27.36% for ACAD. The company reported revenue of $250.4 million for the quarter, compared to $211.7 million a year earlier. Comparatively to last year’s same quarter, the company’s quarterly revenue rose 18.28 percent.
